Full Text (PDF)
Original Article

Ayurvedic Medicines in Global Markets: Legal Provisions, Pharmacovigilance, and Adverse Reactions

Shri Gopal Kabra

Author Information

Licence:

Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.



Indian Journal of Ancient Medicine and Yoga 19(4):p 249-255, Oct - Dec. 2026. | DOI: https://doi.org/10.21088/ijamy.0974.6986.19426.4

How Cite This Article:

Shri Gopal Kabra. Ayurvedic Medicines in Global Markets: Legal Provisions, Pharmacovigilance, and Adverse Reactions. Ind J Anct Med Yoga. 2026; 19(4): 249-255.

Timeline

Received : September 01, 2026         Accepted : October 03, 2026          Published : December 30, 2026

Abstract

Ayurvedic medicines, though widely marketed across Western countries as food supplements, herbal remedies, or traditional health products, are not recognized as licensed pharmaceuticals requiring premarket efficacy disclosure.1 Their legal entry is facilitated through frameworks such as the U.S. Dietary Supplement Health and Education Act (DSHEA), the EU Traditional Herbal Medicinal Products Directive (THMPD), Canada’s Natural Health Products Regulations, and Australia’s complementary medicine listing system.1,2 Despite bypassing premarket drug approval, these products remain under postmarket pharmacovigilance surveillance.1,3 Healthcare providers are obliged to document usage and report adverse reactions to national pharmacovigilance agencies, which collate, analyze, and establish causality using World Health Organization–Uppsala Monitoring Centre (WHO-UMC) criteria.3 Scientific literature has documented major adverse reactions to Ayurvedic supplements, including hepatotoxicity (Tinospora cordifolia, Ashwagandha, Turmeric, Psoralea corylifolia), hypersensitivity reactions, and heavy-metal poisoning (lead, mercury, arsenic).4-6 Case reports from the United States, United Kingdom, and India substantiate these risks, with outcomes ranging from acute liver failure to Cushing’s syndrome due to steroid adulteration.4,7 Indian statutory bodies—including the Ministry of AYUSH, CDSCO, ICMR, and NCISM— have acknowledged these concerns, establishing the Ayush Pharmacovigilance Program of India (APvPI) and issuing guidelines for adverse drug reaction reporting.3,8 This deliberation highlights the tension between traditional use and modern regulatory safeguards, underscoring the need for harmonized global vigilance, transparent labeling, and evidence-based integration of Ayurvedic medicines into healthcare systems.1,8


References

  • 1.   World Health Organization. WHO Global Report on Traditional and Complementary Medicine 2019. World Health Organization; 2019.
  • 2.   WHO Regional Office for Europe. Regulatory Situation of Herbal Medicines: A Worldwide Review. World Health Organization; 1998.
  • 3.   World Health Organization. WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems. World Health Organization; 2004.
  • 4.   Sartori D, Aronson JK, Brand JS, Gauffin O, Hedfors Vidlin S, Norén GN, Onakpoya IJ. Signals of adverse reactions to herbal medicines: evidence and document analysis based on a scoping review. Drug Safety. 2025;48(12):1339– 1352. https://doi.org/10.1007/s40264-025- 01580-3
  • 5.   Ng CYJ. Immediate hypersensitivity to herbal medicine: from diagnosis to policies. Current Opinion in Allergy and Clinical Immunology. 2026;26(4):287–293. https://doi.org/10.1097/ ACI.0000000000001168
  • 6.   Philips CA, Paramaguru R, Joy V, Augustine P. Herb-induced liver injury in ancient Indian systems of medicine: A narrative review of mechanisms, offending agents, and clinical outcomes. Medicine (Baltimore). 2024;103(18):e38012.
  • 7.   Saper RB, Phillips RS, Sehgal A, Khouri N, Davis RB, Paquin J, Thach PW, Kales SN. Heavy metal content of Ayurvedic herbal medicine products. JAMA. 2004;292(23):2868– 2873. https://doi.org/10.1001/jama.292.23. 2868
  • 8.   Ministry of AYUSH, Government of India. Pharmacovigilance Initiatives for Ayush Drugs: Operational Guidelines for National Ayush Pharmacovigilance Program. Ministry of AYUSH; 2018.
  • 9.   Yadav, Pushpa., et al, 62nd Annual Conference of the Indian Society of Gastroenterology, February 10th - 13th, 2022, Pune. Indian J Gastroenterol. 2022 Feb;41(Suppl 1):1-178. doi: 10.1007/s12664-021-01234-z. PMID: 35312950; PMCID: PMC8934723.

Data Sharing Statement

There are no additional data available. All raw data and code are available upon request.

Funding

This research received no funding.

Author Contributions

All authors contributed significantly to the work and approve its publication.

Ethics Declaration

This article does not involve any human or animal subjects, and therefore does not require ethics approval.

Acknowledgements

We would like to express our gratitude to the patients, their families, and all those who have contributed to this study.

Conflicts of Interest

No conflicts of interest in this work.


About this article


Cite this article

Shri Gopal Kabra. Ayurvedic Medicines in Global Markets: Legal Provisions, Pharmacovigilance, and Adverse Reactions. Ind J Anct Med Yoga. 2026; 19(4): 249-255.


Licence:

Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.



Received Accepted Published
September 01, 2026 October 03, 2026 December 30, 2026

DOI: https://doi.org/10.21088/ijamy.0974.6986.19426.4

Keywords

Ayurvedic medicinesHerbal supplementsPharmacovigilanceAdverse drug reactions (ADR)HepatotoxicityHeavy-metal poisoningRegulatory frameworksDietary Supplement Health and Education Act (DSHEA)Traditional Herbal Medicina Products Directive (THMPD)Ayush Pharmacovigilance Program of India (APvPI)

Article Level Metrics

Last Updated

Sunday 22 November 2026, 04:40:54 (IST)


6880

Accesses

8
1075
00

Citations


NA
NA
NA

Download citation


Article Keywords


Keyword Highlighting

Highlight selected keywords in the article text.


Timeline


Received September 01, 2026
Accepted October 03, 2026
Published December 30, 2026

licence


Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.



Access this article



Share